Drug intelligence / Profile preview

BC3402 + azacitidine

Development stage: Unknown
Lead developer: Biocity Biopharmaceutics
Modality: Small Molecules
Administration: Intravenous

Overview

BC3402 + azacitidine is a combination investigational therapy being evaluated for safety, pharmacokinetics, pharmacodynamics, and efficacy in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)[1][3]. BC3402 is a novel agent (precise mechanism not disclosed in public trial records) and azacitidine is a DNA demethylating small molecule used to treat bone marrow disorders; azacitidine inhibits DNA methyltransferase and incorporates into RNA and DNA to exert anti-neoplastic and cytotoxic effects[2][6]. The combination is administered intravenously in clinical trials targeting patients ineligible for stem cell transplantation[1][3].

Other names: BC3402 + azacitidine

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)

Beyond the preview

Go deeper on BC3402 + azacitidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BC3402 + azacitidine.

Explore the full profile